Document Detail


Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening.
MedLine Citation:
PMID:  22059988     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Highly sensitive and specific radioimmunoassays have been validated for autoantibodies reacting with the four major autoantigens identified so far in autoimmune diabetes. However, the analysis of this large number of autoantigens has increased the costs and time necessary for complete autoantibody screenings. Our aim was to demonstrate that it is possible to detect the immunoreactivity against a combination of four different autoantigens by a single assay, this representing a rapid, low-cost first approach to evaluate humoral autoimmunity in diabetes. By using this novel multi-autoantigen radioimmunoassay (MAA), in subsequent steps we analysed 830 sera, 476 of known and 354 of unknown diabetes-specific immunoreactivity, collected from various groups of individuals including type 1 and type 2 diabetes patients, autoantibody-positive patients with a clinical diagnosis of type 2 diabetes (LADA), prediabetic subjects, individuals at risk to develop autoimmune diabetes, siblings of type 1 diabetic patients, coeliac patients and healthy control subjects. All sera reacting with one or more of the four autoantigens by single assays also resulted positive with MAA, as well as eight of 24 type 1 diabetic patients classified initially as autoantibody-negative at disease onset based on single autoantibody assays. In addition, MAA showed 92% sensitivity and 99% specificity by analysing 140 blinded sera from type 1 diabetic patients and control subjects provided in the 2010 Diabetes Autoantibody Standardization Program. MAA is the first combined method also able to evaluate, in addition to glutamic acid decarboxylase (GAD) and tyrosine phosphatase (IA)-2, insulin and islet beta-cell zinc cation efflux transporter (ZnT8) autoantibodies. It appears to be particularly appropriate as a first-line approach for large-scale population-based screenings of anti-islet autoimmunity.
Authors:
C Tiberti; L Yu; F Lucantoni; F Panimolle; I Spagnuolo; A Lenzi; G S Eisenbarth; F Dotta
Related Documents :
20012788 - Diabetic ketoacidosis, thyroiditis and alopecia areata in a child with down syndrome.
406008 - Menstruation and control of diabetes.
1931548 - Persistent normal anion gap acidosis in the recovery phase of diabetic ketoacidosis.
9388398 - Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependen...
12601068 - The effect of ischemic preconditioning on light-induced photoreceptor injury.
16322398 - Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics af...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  166     ISSN:  1365-2249     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  317-24     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.
Affiliation:
Department of Clinical Sciences Department of Physiopathology, University of Rome 'Sapienza', Rome Diabetes Unit, Department of Internal Medicine, Endocrine and Metabolic Sciences and Biochemistry, University of Siena Umberto Di Mario ONLUS Research Foundation, Toscana Life Science Park, Siena, Italy Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, CO, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary...
Next Document:  2?-Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D(3) protects the insulin 2 knockout non-obese diabeti...